Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002375320 | SCV002686102 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-08-19 | criteria provided, single submitter | clinical testing | The c.9145dupT pathogenic mutation, located in coding exon 23 of the BRCA2 gene, results from a duplication of T at nucleotide position 9145, causing a translational frameshift with a predicted alternate stop codon (p.Y3049Lfs*23). This alteration was detected in 1/7400 high-risk Czech breast/ ovarian cancer families (Machackova E et al. Klin Onkol. 2019;32:51-71). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
CZECANCA consortium | RCV001271065 | SCV001451890 | pathogenic | Breast and/or ovarian cancer | 2019-06-11 | no assertion criteria provided | clinical testing |